Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis

Published:2019-07 Issue: Volume:209 Page:50-57
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Matsui Kentaro,Tokumasu Takahiro,Takekita Yoshiteru^ORCID,Inada Ken,Kanazawa Tetsufumi^ORCID,Kishimoto Taishiro,Takasu Shotaro,Tani Hideaki,Tarutani Seiichiro^ORCID,Hashimoto Naoki,Yamada Hiroki,Yamanouchi Yoshio,Takeuchi Hiroyoshi^ORCID

Funder

Health and Labor Sciences Research Grants

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference48 articles.

1. A rating scale for drug-induced akathisia;Barnes;Br. J. Psychiatry,1989

2. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis;Bartoli;J. Psychiatr. Res.,2019

3. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study;Borlido;J. Clin. Psychiatry,2016

4. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements;Buchanan;Schizophr. Bull.,2010

5. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents;Buckley;J. Clin. Psychiatry,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials;Schizophrenia Research;2024-08

2. Deprescribing: An umbrella review;Acta Pharmaceutica;2024-05-30

3. Drug Treatment of the Psychoses;Seminars in General Adult Psychiatry;2024-03-31

4. Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics);Tasman’s Psychiatry;2024

5. Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia;Neuropsychopharmacology Reports;2023-07-14